Aging is a crucial risk factor for common neurodegenerative diseases, such as Alzheimer's
disease (AD) and Parkinson's disease (PD). Limited options are available for the treatment …

The current understanding of neurodegenerative processes in sporadic diseases such as
Alzheimer's disease (AD), Parkinson's disease (PD) or multiple sclerosis is very limited …

Highlights•GLP-1 analogs can cross the blood–brain barrier and stimulate the GLP-1
receptor in the brain.•Stimulation of the GLP-1 receptor has shown effects on mitochondrial …

Type 2 diabetes mellitus and the associated desensitisation of insulin signalling has been
identified as a risk factor for progressive neurodegenerative disorders such as Alzheimer's …

Recent clinical guidelines have emphasized the importance of screening for cognitive
impairment in older adults with diabetes, however, there is still a lack of understanding about …

Like type‐2 diabetes mellitus (T2DM), neurodegenerative disorders and stroke are an ever
increasing, health, social and economic burden for developed Westernized countries. Age is …

Introduction: Epidemiological evidence suggests an association between type 2 diabetes
(T2DM) and Alzheimer's disease (AD), in that one disease increases the risk of the other …

The link between diabetes mellitus and Alzheimer's disease (AD) has been known for the
last few decades. Since insulin and insulin receptors are known to be present in the brain …

Diabetes mellitus is one of the major risk factors for cognitive dysfunction. The pathogenesis
of brain impairment caused by chronic hyperglycemia is complex and includes …

The incretin hormone glucagon-like peptide 1 (GLP-1) has many effects in the body. It is best
known for the 'incretin effect', facilitating insulin release from the pancreas under …